Revolution Medicines (NASDAQ:RVMD) Insider Xiaolin Wang Sells 2,010 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) insider Xiaolin Wang sold 2,010 shares of the stock in a transaction on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $199,954.80. Following the sale, the insider owned 116,063 shares of the company’s stock, valued at approximately $11,545,947.24. This trade represents a 1.70% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Revolution Medicines Stock Performance

Shares of RVMD opened at $98.55 on Friday. The company has a current ratio of 7.14, a quick ratio of 7.14 and a debt-to-equity ratio of 0.16. The firm’s fifty day simple moving average is $103.42 and its two-hundred day simple moving average is $76.40. Revolution Medicines, Inc. has a 12 month low of $29.17 and a 12 month high of $124.49. The stock has a market capitalization of $19.53 billion, a P/E ratio of -16.67 and a beta of 0.99.

Revolution Medicines (NASDAQ:RVMD) last announced its quarterly earnings data on Wednesday, February 25th. The company reported ($1.86) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same quarter in the prior year, the business earned ($1.12) earnings per share. As a group, analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Analyst Ratings Changes

A number of research analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Revolution Medicines in a research report on Thursday, January 22nd. UBS Group initiated coverage on shares of Revolution Medicines in a report on Friday, February 27th. They set a “buy” rating on the stock. Jefferies Financial Group started coverage on Revolution Medicines in a research note on Monday. They issued a “buy” rating for the company. Evercore raised Revolution Medicines to a “strong-buy” rating in a research note on Wednesday, February 25th. Finally, Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a report on Tuesday, February 17th. Four research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $78.94.

Key Stories Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Large institutional buys and heavy institutional ownership (General Atlantic, Norges Bank, Avoro, UBS, Polar Capital and others acquired meaningful stakes or added materially), signaling strong institutional conviction that can support the stock. MarketBeat Institutional/Insider Summary
• Positive Sentiment: Analyst coverage is largely bullish — multiple recent upgrades/initiations (Evercore, Jefferies, UBS, Benchmark) and a consensus “Buy” bias among analysts, which can underpin buying interest and price support. Analyst Coverage Summary
• Neutral Sentiment: Company profile and pipeline: clinical-stage biotech focused on RAS-pathway therapies (RMC-4630, RMC-6291, RMC-6236). Positive long-term potential but clinical/readout risk remains — typical for development-stage biotechs. Company Profile
• Neutral Sentiment: Recent quarterly report (Feb. 25) showed a wider loss (EPS -$1.86) and missed estimates — a reminder of ongoing cash burn and execution risk; analysts expect negative FY EPS. Earnings Summary
• Negative Sentiment: Several senior insiders sold shares on Mar. 17 (large disclosed Form 4s). Mark A. Goldsmith sold 12,871 shares (~$1.28M). SEC filing: Goldsmith SEC Filing
• Negative Sentiment: COO Margaret A. Horn sold 4,583 shares (~$456K). SEC filing: Horn SEC Filing
• Negative Sentiment: Stephen M. Kelsey sold 4,302 shares (~$428K). SEC filing: Kelsey SEC Filing
• Negative Sentiment: CFO Jack Anders sold 2,753 shares (~$274K). SEC filing: Anders SEC Filing
• Negative Sentiment: Insiders Xiaolin Wang and Lin Wei also sold smaller stakes (2,010 and 2,073 shares). SEC filings: Wang SEC Filing · Wei SEC Filing

Hedge Funds Weigh In On Revolution Medicines

Hedge funds have recently bought and sold shares of the company. General Atlantic L.P. purchased a new stake in shares of Revolution Medicines in the third quarter valued at about $115,556,000. Norges Bank bought a new stake in Revolution Medicines in the 4th quarter worth about $195,568,000. Avoro Capital Advisors LLC purchased a new stake in Revolution Medicines in the 4th quarter valued at about $172,840,000. UBS Group AG lifted its position in shares of Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock worth $245,954,000 after buying an additional 1,998,972 shares in the last quarter. Finally, Polar Capital Holdings Plc boosted its stake in shares of Revolution Medicines by 321.2% in the 4th quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock worth $160,398,000 after buying an additional 1,535,686 shares during the last quarter. 94.34% of the stock is owned by hedge funds and other institutional investors.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.